|
|
|
|
| LEADER |
04795nam a2200673 4500 |
| 001 |
on1003131132 |
| 003 |
OCoLC |
| 005 |
20180501122037.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170907s2017 maua ob 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d IDEBK
|d EBLCP
|d OPELS
|d N$T
|d OCLCF
|d YDX
|d OHS
|d OCLCO
|d MEU
|d GrThAP
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1003254078
|a 1028912886
|a 1030777589
|
| 020 |
|
|
|a 9780128119235
|q (electronic bk.)
|
| 020 |
|
|
|a 0128119233
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128119228
|
| 020 |
|
|
|a 0128119225
|
| 035 |
|
|
|a (OCoLC)1003131132
|z (OCoLC)1003254078
|z (OCoLC)1028912886
|z (OCoLC)1030777589
|
| 050 |
|
4 |
|a RC268.4
|b .M57 2017eb
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4042
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a miRNA and Cancer /
|c edited by Carlo M. Croce, Paul B. Fisher.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press, is imprint of Elsevier,
|c [2017].
|
| 264 |
|
4 |
|c Ã2017
|
| 300 |
|
|
|a 1 online resource (xi, 220 pages :
|b illustrations).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in cancer research ;
|v Volume 135
|
| 546 |
|
|
|a Text in English.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
8 |
|
|a 6.4. MDA-7/IL-246.5. hPNPase; 6.6. hnRNPA1; 6.7. ADARs; 6.8. Stress; 6.9. Diet and Natural Products; 7. Conclusions and Future Perspectives; Acknowledgments; References; Chapter Three: Animal Models to Study MicroRNA Function; 1. Introduction; 1.1. MicroRNA Biogenesis, Mechanism of Action and Function; 1.1.1. Biogenesis; 1.1.1.1. Expression of MiRNA Genes; 1.1.1.1.1. Regulation Mediated by Availability of Transcription Factors; 1.1.1.1.2. Regulation Mediated by Genomic Location of MiRNA Genes; 1.1.1.1.2.1. Location in the Epigenome; 1.1.1.1.2.2. Location Relative to Host Genes
|
| 505 |
8 |
|
|a 1.1.1.1.2.3. Regulation by MiRNA Copy Number1.1.1.1.2.4. Cancer-Associated Genomic Regions; 1.1.1.2. Process of Biogenesis; 1.1.2. Mechanisms of Action and Functions of MiRNAs; 1.1.2.1. Incorporation Into miRISC and Targeting; 1.1.2.2. The Role of Family Members in Expression and Targeting; 1.1.2.3. The Role of MiRNA Clusters and Paralogous in Targeting; 1.1.2.4. Use of Bioinformatics to Elucidate MiRNA Function; 1.2. MiRNA Function and Relevance in Cancer; 1.2.1. OncomiRs; 1.2.2. Tumor-Suppressive MiRNA; 1.3. Tools That Advanced MiRNA Research
|
| 505 |
8 |
|
|a 2. Generation of Model Organisms and Their Use in MiRNA Functional Studies2.1. Caenorhabditis elegans; 2.1.1. Generation of Transgenic C. elegans for Use in MiRNA Functional Studies; 2.1.2. C. elegans as a Model System for Studying the Function of MiRNAs in Cancer; 2.2. Drosophila melanogaster (Fruit Flies); 2.2.1. Generation of Transgenic D. melanogaster to Model Cancer Phenotypes; 2.2.2. D. melanogaster as a Model for Studying the Functions of MiRNAs in Cancer; 2.3. Danio rerio (Zebrafish); 2.3.1. Generation of Transgenic D. rerio for Use in MiRNA Functional Research
|
| 505 |
8 |
|
|a 2.3.2. D. rerio as a Model for Studying the Function of MiRNA in Cancer2.4. Mus musculus (Mouse); 2.4.1. Generation of Transgenic M. musculus for Use in MiRNA Functional Research; 2.4.1.1. Genetically Engineered Mouse Models Generated via Transgenesis; 2.4.1.2. GEMMs Generated via Homologous Recombination; 2.4.2. Strategies Utilized to Generate Gene-Targeting Vectors; 2.4.2.1. Cre-LoxP System; 2.4.2.2. Flp-FRT System; 2.4.2.3. Inducible Systems; 2.4.2.3.1. Tetracycline ON/OFF System; 2.4.2.3.2. Cre-ER(T) System; 2.4.3. Using M. musculus for MiRNA Functional Studies in Cancer; 3. Conclusion
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed September 13, 2017).
|
| 650 |
|
0 |
|a Cancer
|x Genetic aspects.
|
| 650 |
|
0 |
|a Cancer genes.
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer genes.
|2 fast
|0 (OCoLC)fst01765208
|
| 650 |
|
7 |
|a Cancer
|x Genetic aspects.
|2 fast
|0 (OCoLC)fst00845368
|
| 650 |
|
2 |
|a Neoplasms
|x genetics.
|0 (DNLM)D009369Q000235
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Croce, Carlo,
|e editor.
|
| 700 |
1 |
|
|a Fisher, Paul B.,
|e editor.
|
| 776 |
0 |
8 |
|c Original
|z 9780128119228
|z 0128119225
|w (OCoLC)974699144
|
| 830 |
|
0 |
|a Advances in cancer research ;
|v v. 135.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/0065230X/135
|z Full Text via HEAL-Link
|
